Results of a Phase II Trial of Brentuximab Vedotin for CD30<sup>+</sup> Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis - Concepedia

Concepedia

Publication | Open Access

Results of a Phase II Trial of Brentuximab Vedotin for CD30<sup>+</sup> Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis

DOI Full Paper Access

293

Citations

22

References

2015

Year

Madeleine Duvic, Michael T. Tetzlaff, Pamela Gangar, Audra L. Clos, Dawen Sui, Rakhshandra Talpur

Journal of Clinical Oncology

Abstract

Brentuximab vedotin is both active and well tolerated in cutaneous T-cell lymphoma and lymphomatoid papulosis, with an overall response rate of 73% and complete response rate of 35%.

References

	Year	Citations

Page 1